4种喹诺酮类药物治疗呼吸系统感染成本-效果分析  

Cost-Effectiveness Analysis of Four Kinds of Quinolone Drug in Treatment of Respiratory System Infection

作　　者：李秀英[1] 许恒忠[1] 闫玉琴[1] 

机构地区：[1]山东省聊城市第二人民医院药剂科,山东临清252601

出　　处：《中国药业》2010年第16期50-52,共3页China Pharmaceuticals

摘　　要：目的比较4种喹诺酮类药物治疗呼吸系统感染的成本-效果。方法采用回顾性研究方法,选择120例呼吸系统感染患者,随机分为A(门冬氨酸洛美沙星)、B(甲磺酸帕珠沙星)、C(盐酸左氧氟沙星)、D(氟罗沙星)4组,进行成本-效果分析。结果 A,B,C,D组的成本分别为872.48,716.80,512.40,562.80元,临床有效率分别为93.33%,90.00%,86.67%,83.33%,成本-效果比分别为9.35,7.96,5.91,6.75。以D组为参照,A,B,C组的增量成本-效果比分别是30.97,23.09,-15.09。结论 C组治疗方案(左氧氟沙星)较经济合理。Objective To analyze the expenses and effect of four kinds of quinolone drug in treatment of respiratory system infection. Methods The retrospective study was performed. A total of 120 patients with respiratory system infection receiving chemotherapy were randomly assigned to lomefloxacin aspartate （group A）,pazufloxacin mesylate （group B）,levofloxacin hydrochloride （group C）,or fleroxacin （ group D） ,respectively. The therapeutic effects were monitored and the cost-effectiveness analyses were conducted on the four groups. Results The costs of four groups were 872. 48,716. 80,512. 40,562. 80 yuan,respectively. The effective rates of four groups were 93. 33% , 90. 00%,86. 67% and 83. 33%,respectively. The cost-effectiveness ratios of four groups were 9. 35,7. 96,5. 91 and 6. 75,respectively. Compared with group D,incremental cost-effectiveness ratios of group A,B,C were 30. 97,23. 09,-15. 09,respectively. Conclusion Group C was the most reasonable option among the four groups.

关 键 词：喹诺酮类药物 呼吸系统感染 成本-效果分析 

分 类 号：F407.7[经济管理—产业经济] R969.3[医药卫生—药理学]